Outcomes of curative surgery and adjuvant radiation therapy in salivary duct carcinoma.

IF 1.3
Divyani Chowdhury, Nivedita Sarkar, Pasupuleti H H M Sai Hanuman, Avinaba Sinha, Sudipta Pati, Sanjoy Chatterjee, Prateek V Jain, Pattatheyil Arun, Paromita Roy, Indu Arun, Indranil Mallick
{"title":"Outcomes of curative surgery and adjuvant radiation therapy in salivary duct carcinoma.","authors":"Divyani Chowdhury, Nivedita Sarkar, Pasupuleti H H M Sai Hanuman, Avinaba Sinha, Sudipta Pati, Sanjoy Chatterjee, Prateek V Jain, Pattatheyil Arun, Paromita Roy, Indu Arun, Indranil Mallick","doi":"10.4103/jcrt.jcrt_1842_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Salivary duct carcinoma (SDC) forms an uncommon and aggressive subtype of salivary gland neoplasms with early recurrences and metastases. Their treatment includes surgery and adjuvant radiotherapy. They overexpress androgen receptors (AR) and human epidermal receptor 2 (HER2), similar to breast carcinomas. There is limited data on SDCs treated with curative intent from Asia.</p><p><strong>Objective: </strong>In this retrospective analysis, we reviewed SDCs treated between 2012 and 2022. The aim of this study was to study the outcome of SDCs in patients who were treated with curative intent. The primary objectives of the study were to study the overall survival (OS) and disease-free survival (DFS) in patients of salivary duct cancer treated with curative intent, compare OS and DFS among various groups, and identify certain critical clinical or pathological attributes that may affect disease outcomes.</p><p><strong>Materials and methods: </strong>Patient demographics, tumor characteristics, treatment details, and outcomes were recorded for 48 patients in REDCap (electronic data collection system) and all eligible patients were contacted for survival status.</p><p><strong>Statistical analysis: </strong>Statistical analysis was done using SPSS software and survival analysis using the log-rank test and Cox regression.</p><p><strong>Results: </strong>After a median follow-up of 13.8 months ranging from 0.5 to 125.2 months, median DFS and OS were 11.4 and 13.8 months. Node (s) positive patients showed numerically inferior DFS, 66.6% vs. 81.7% at one year and 22.8% vs. 67.4% at two years (P = 0.061) with a hazard ratio (HR) 2.23 (95% confidence interval [CI]: 0.94-5.29, P = 0.068) and inferior OS, 91.7% vs. 100% at one year and 72.2% vs. 86.7% at two years (P = 0.068) with HR 3.41 (95% CI: 0.84-13.79, P = 0.085). Patients with extranodal extension had numerically inferior DFS, 59.1% vs. 85.9% (P = 0.119) with HR 1.96 (95% CI of 0.82-4.68, P = 0.126) and lower OS, 90.9% vs. 100% (P = 0.112) at one year with HR 2.96 (95% CI of 0.72-12.02, P = 0.129). Despite the large numerical difference, the P value was not statistically significant due to limited sample size.</p><p><strong>Conclusion: </strong>Salivary duct cancers, even when treated curatively, have early and distant failures. Over-expression of HER2-neu and AR provide an opportunity to improve the outcomes of curative intent treatment for this cancer with targeted agents and robust data is required to investigate the role of adjuvant endocrine or HER-2 targeted therapies.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"670-677"},"PeriodicalIF":1.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer research and therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jcrt.jcrt_1842_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Salivary duct carcinoma (SDC) forms an uncommon and aggressive subtype of salivary gland neoplasms with early recurrences and metastases. Their treatment includes surgery and adjuvant radiotherapy. They overexpress androgen receptors (AR) and human epidermal receptor 2 (HER2), similar to breast carcinomas. There is limited data on SDCs treated with curative intent from Asia.

Objective: In this retrospective analysis, we reviewed SDCs treated between 2012 and 2022. The aim of this study was to study the outcome of SDCs in patients who were treated with curative intent. The primary objectives of the study were to study the overall survival (OS) and disease-free survival (DFS) in patients of salivary duct cancer treated with curative intent, compare OS and DFS among various groups, and identify certain critical clinical or pathological attributes that may affect disease outcomes.

Materials and methods: Patient demographics, tumor characteristics, treatment details, and outcomes were recorded for 48 patients in REDCap (electronic data collection system) and all eligible patients were contacted for survival status.

Statistical analysis: Statistical analysis was done using SPSS software and survival analysis using the log-rank test and Cox regression.

Results: After a median follow-up of 13.8 months ranging from 0.5 to 125.2 months, median DFS and OS were 11.4 and 13.8 months. Node (s) positive patients showed numerically inferior DFS, 66.6% vs. 81.7% at one year and 22.8% vs. 67.4% at two years (P = 0.061) with a hazard ratio (HR) 2.23 (95% confidence interval [CI]: 0.94-5.29, P = 0.068) and inferior OS, 91.7% vs. 100% at one year and 72.2% vs. 86.7% at two years (P = 0.068) with HR 3.41 (95% CI: 0.84-13.79, P = 0.085). Patients with extranodal extension had numerically inferior DFS, 59.1% vs. 85.9% (P = 0.119) with HR 1.96 (95% CI of 0.82-4.68, P = 0.126) and lower OS, 90.9% vs. 100% (P = 0.112) at one year with HR 2.96 (95% CI of 0.72-12.02, P = 0.129). Despite the large numerical difference, the P value was not statistically significant due to limited sample size.

Conclusion: Salivary duct cancers, even when treated curatively, have early and distant failures. Over-expression of HER2-neu and AR provide an opportunity to improve the outcomes of curative intent treatment for this cancer with targeted agents and robust data is required to investigate the role of adjuvant endocrine or HER-2 targeted therapies.

涎腺管癌手术及辅助放疗的疗效分析。
涎腺导管癌(SDC)是唾液腺肿瘤中一种罕见的侵袭性亚型,具有早期复发和转移。他们的治疗包括手术和辅助放疗。它们过表达雄激素受体(AR)和人表皮受体2 (HER2),与乳腺癌相似。亚洲以治疗目的治疗的SDCs数据有限。目的:在这项回顾性分析中,我们回顾了2012年至2022年期间治疗的sdc。本研究的目的是研究以治愈为目的治疗的sdc患者的预后。本研究的主要目的是研究以治愈为目的治疗的唾液管癌患者的总生存期(OS)和无病生存期(DFS),比较不同组间的OS和DFS,并确定可能影响疾病结局的某些关键临床或病理属性。材料和方法:在REDCap(电子数据收集系统)中记录48例患者的患者人口统计学、肿瘤特征、治疗细节和结局,并联系所有符合条件的患者了解生存状况。统计学分析:采用SPSS软件进行统计学分析,采用log-rank检验和Cox回归进行生存分析。结果:中位随访时间为13.8个月,范围为0.5 ~ 125.2个月,中位DFS和OS分别为11.4和13.8个月。淋巴结(s)阳性患者的DFS数值较差,1年时66.6%比81.7%,2年时22.8%比67.4% (P = 0.061),风险比(HR) 2.23(95%可信区间[CI]: 0.94-5.29, P = 0.068), OS较差,1年时91.7%比100%,2年时72.2%比86.7% (P = 0.068),风险比为3.41 (95% CI: 0.84-13.79, P = 0.085)。结外延伸患者的DFS数值较低,分别为59.1%对85.9% (P = 0.119), HR为1.96 (95% CI为0.82-4.68,P = 0.126), OS较低,90.9%对100% (P = 0.112),一年的HR为2.96 (95% CI为0.72-12.02,P = 0.129)。尽管数值差异很大,但由于样本量有限,P值没有统计学意义。结论:唾液管癌,即使治疗有效,也有早期和远期的失败。HER2-neu和AR的过表达为靶向药物改善这种癌症的疗效提供了机会,并且需要可靠的数据来研究辅助内分泌或HER-2靶向治疗的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信